Provided by Tiger Trade Technology Pte. Ltd.

SPYRE THERAPEUTICS INC

88.14
-2.2250-2.46%
Volume:796.14K
Turnover:70.32M
Market Cap:7.77B
PE:-43.85
High:90.97
Open:89.15
Low:87.05
Close:90.36
52wk High:110.18
52wk Low:14.51
Shares:88.17M
Float Shares:80.98M
Volume Ratio:0.84
T/O Rate:0.98%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-2.0100
EPS(LYR):-1.9755
ROE:-22.98%
ROA:-19.81%
PB:8.14
PE(LYR):-44.61

Loading ...

Analysts Offer Insights on Healthcare Companies: Revolution Medicines (RVMD) and Spyre Therapeutics (SYRE)

TIPRANKS
·
Aug 29

U.S. Research Roundup-CrowdStrike, Nvidia, Macerich

Reuters
·
Aug 27

Top Midday Decliners

MT Newswires Live
·
Aug 27

Spyre Therapeutics falls -13.2%

TIPRANKS
·
Aug 27

Spyre Therapeutics Down over 12%, on Pace for Largest Percent Decrease Since June 2024

Dow Jones
·
Aug 26

U.S. Stocks on the MOVE-Semtech, Donaldson, Meta

Reuters
·
Aug 26

Spyre Therapeutics (SYRE) Gets a Buy from LifeSci Capital

TIPRANKS
·
Aug 26

Analysts Offer Insights on Healthcare Companies: Solventum Corporation (SOLV), Argenx Se (ARGX) and Spyre Therapeutics (SYRE)

TIPRANKS
·
Aug 26

Spyre Therapeutics Reports Phase 2 Skyway RA Data for Spy072 Shows Statistically Significant Benefit vs Placebo

Reuters
·
Aug 26

Spyre Therapeutics Shares Down 12.4% Premarket After Co's Experimental Drug Fails to Meet Threshold for Monotherapy Development in Rheumatoid Arthritis

THOMSON REUTERS
·
Aug 26

Spyre Therapeutics Inc : Btig Cuts Target Price to $121 from $132

THOMSON REUTERS
·
Aug 26

Stocks to Watch: Intuit, Spyre Therapeutics, Zoom Communications, nCino

Dow Jones
·
Aug 26

Spyre Therapeutics Stock (SYRE) Tumbles 14% in After-Hours – Here’s What Spooked Investors

TIPRANKS
·
Aug 26

Spyre Therapeutics Won't Prioritize Rheumatoid Arthritis Monotherapy After Trial

Dow Jones
·
Aug 26

Spyre Therapeutics announces results from RA sub-study of SKYWAY basket trial

TIPRANKS
·
Aug 26

Spyre Therapeutics Announces Topline Results from the Rheumatoid Arthritis Sub-Study of the Skyway Phase 2 Trial of Spy072

THOMSON REUTERS
·
Aug 26

Spyre Therapeutics - Spy072 Well Tolerated with Adverse Event Rates Comparable to Placebo

THOMSON REUTERS
·
Aug 26

Spyre Therapeutics Inc: Spy072 in Combination with Il17-a/F in Hidradenitis Suppurativa (Hs) in Late 2027 or Early 2028

THOMSON REUTERS
·
Aug 26

Spyre Therapeutics - Topline Data for Spy072 in Psa and Axspa Expected Q4 2026

THOMSON REUTERS
·
Aug 26

Spyre Therapeutics Inc - Magnitude of Effect Did not Meet Company's Target to Prioritize Monotherapy Development of Spy072 in Rheumatoid Arthritis

THOMSON REUTERS
·
Aug 26